Edition:
United Kingdom

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.12USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$0.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
243,398
52-wk High
$2.56
52-wk Low
$0.10

Latest Key Developments (Source: Significant Developments)

Quilter PLC Reports An 11 Pct Passive Stake In Contravir Pharmaceuticals As Of March 05, 2019
Friday, 15 Mar 2019 

March 15 (Reuters) - ContraVir Pharmaceuticals Inc ::QUILTER PLC REPORTS AN 11 PERCENT PASSIVE STAKE IN CONTRAVIR PHARMACEUTICALS AS OF MARCH 05, 2019 - SEC FILING.  Full Article

Contravir Pharmaceuticals Inc Files For Mixed Shelf Of Upto $100 Mln
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

ContraVir Pharmaceuticals Appointed Robert Foster As A Director Of Co On Nov 6 - SEC Filing
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS SAYS ON NOV 6, BOARD REMOVED 'ACTING' FROM ROBERT FOSTER'S TITLE AS CEO; APPOINTED FOSTER AS A DIRECTOR OF CO - SEC FILING.  Full Article

Contravir Pharma Files For Series C Convertible Preferred Stock
Friday, 18 May 2018 

May 18 (Reuters) - ContraVir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING.  Full Article

Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock
Friday, 9 Mar 2018 

March 9 (Reuters) - Contravir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING.  Full Article

ContraVir Pharmaceuticals Reaches Agreement With The FDA
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Contravir Pharmaceuticals Inc ::CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY.CONTRAVIR PHARMACEUTICALS - FDA ALLOWS CO TO USE 505(B)(2) REGULATORY PATHWAY TO STREAMLINE DEVELOPMENT & REGISTRATION OF TXL FOR TREATING CHRONIC HEPATITIS B.  Full Article

Contravir Pharmaceuticals receives HBV IND approval for tenofovir exalidex in the U.S.
Monday, 11 Sep 2017 

Sept 11 (Reuters) - Contravir Pharmaceuticals Inc ::Contravir Pharmaceuticals receives hbv ind approval for tenofovir exalidex (txl™) in the United States.Contravir Pharmaceuticals - ‍intends to initiate U.S.-based clinical trial for txl in q4 of 2017, pending approval by institutional review board​.Contravir Pharmaceuticals - ‍ intends to initiate its first us-based clinical trial for txl in Q4 2017, pending approval by institutional review board​.  Full Article

U.K. accepts Contravir Pharma's clinical trial application
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Contravir Pharmaceuticals Inc :Contravir Pharmaceuticals announces acceptance of clinical trial application in the United Kingdom.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.Contravir Pharmaceuticals Inc - ‍contravir expects to dose its first patient in uk before end of this month​.  Full Article